Effects of fluorouracil, doxorubicin and FAM combination on human peritoneal macrophages

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Anticancer drugs, including fluorouracil, adriamycin, and mitomycin (FAM), are crucial in cancer treatment.
• The impact of these chemotherapy agents on immune cell function, specifically phagocytosis, requires thorough investigation.
• Tissue macrophages play a vital role in immune surveillance and pathogen clearance.

Purpose of the Study:

• To investigate the in vitro effects of fluorouracil, adriamycin, and the FAM combination on the phagocytic activity of human peritoneal macrophages (HPM).
• To compare the phagocytic response of HPM with previously observed effects on blood monocytes exposed to the same anticancer drugs.

Main Methods:

• Human peritoneal macrophages (HPM) were isolated from cancer patients and patients undergoing peritoneal dialysis.
• HPM were incubated with fluorouracil, adriamycin, or the FAM combination in vitro.
• Phagocytosis of yeast cells by HPM was assessed using a fluorescence quenching technique to evaluate adherence, engulfment, and total phagocytosis.

Main Results:

• No significant inhibition of yeast cell adherence, engulfment, or total phagocytosis was observed in HPM treated with fluorouracil, adriamycin, or the FAM combination.
• These findings contrast with previous in vitro studies showing drug-induced inhibition of phagocytosis in blood monocytes.
• The results indicate that HPM exhibit a different sensitivity profile to these anticancer drugs compared to blood monocytes.

Conclusions:

• Human peritoneal macrophages demonstrate resistance to the phagocytosis-inhibiting effects of fluorouracil, adriamycin, and the FAM combination in vitro.
• The observed heterogeneity in drug sensitivity among different macrophage populations may be attributed to variations in cell maturity and surface characteristics.
• Further research is warranted to elucidate the mechanisms underlying differential drug responses in various immune cell subsets.